Rational Combination of Immunotherapies with Clinical Efficacy in Mice with Advanced Cancer.

abstract：:The FDA-AACR Oncology Dose-Finding Workshop, Part 3, was held in Washington, DC, on July 20, 2017, as a continuation of the previous two collaborative dose-finding and optimization workshops presented by the FDA and AACR. This year's workshop focused on combination therapy with immune-oncology agents and best practice...

journal_title：Cancer immunology research

authors： Emens LA,Bruno R,Rubin EH,Jaffee EM,McKee AE

更新日期：2017-12-01 00:00:00

abstract：:Monocytes may contribute to tumor progression in part by mediating tumor-induced immunosuppression. Alterations to the monocyte populations and functions in untreated patients with late-stage melanoma are not fully understood. To characterize these alterations, we compared the frequency, phenotype, and functional capa...

journal_title：Cancer immunology research

authors： Chavan R,Salvador D,Gustafson MP,Dietz AB,Nevala W,Markovic SN

更新日期：2014-03-01 00:00:00

abstract：:Cancer immunology has recently made major therapeutic inroads that represent clinical application of basic insights into mechanisms that govern immunity against tumors. Research into fundamental elements of T-cell and natural killer-cell biology, including the basis of antigen recognition, activation, proliferation, a...

journal_title：Cancer immunology research

authors： Kim HJ,Cantor H

更新日期：2014-10-01 00:00:00

abstract：:Pneumonitis may complicate anti-programmed death-1 (PD-1) therapy, although symptoms usually resolve with steroids. The long-term effects on respiratory function, however, are not well defined. We screened melanoma patients treated with anti-PD-1, with and without ipilimumab (anti-CTLA-4), and identified 31 patients w...

journal_title：Cancer immunology research

authors： Johnson DB,Taylor KB,Cohen JV,Ayoubi N,Haugh AM,Wang DY,Schlick BD,Voorhees AL,Gage KL,Fintelmann FJ,Sullivan RJ,Eroglu Z,Abramson RG

更新日期：2019-11-01 00:00:00

abstract：:High levels of human telomerase reverse transcriptase (hTERT) are detected in more than 85% of human cancers. Immunologic analysis supports that hTERT is a widely applicable target recognized by T cells and can be potentially studied as a broad cancer immunotherapeutic, or a unique line of defense against tumor recurr...

journal_title：Cancer immunology research

authors： Yan J,Pankhong P,Shin TH,Obeng-Adjei N,Morrow MP,Walters JN,Khan AS,Sardesai NY,Weiner DB

更新日期：2013-09-01 00:00:00

abstract：:Tertiary lymphoid structures (TLS) are ectopic lymphoid aggregates that phenotypically resemble conventional secondary lymphoid organs and are commonly found at sites of chronic inflammation. They are also found in a wide variety of primary and metastatic human tumors. The presence of tumor-associated TLS (TA-TLS) is ...

journal_title：Cancer immunology research

authors： Rodriguez AB,Engelhard VH

更新日期：2020-11-01 00:00:00

abstract：:Chimeric antigen receptor (CAR) T-cell therapy is effective in the treatment of cancers of hematopoietic origin. In the immunosuppressive solid tumor environment, CAR T cells encounter obstacles that compromise their efficacy. We developed a strategy to address these barriers by having CAR T cells secrete single-domai...

journal_title：Cancer immunology research

authors： Xie YJ,Dougan M,Ingram JR,Pishesha N,Fang T,Momin N,Ploegh HL

更新日期：2020-04-01 00:00:00

abstract：:Accumulating preclinical and clinical evidence indicates that the success of several anticancer agents-including some conventional chemotherapeutics, targeted anticancer agents as well as specific forms of radiotherapy-depends (at least in part) on their ability to stimulate anticancer immune responses. Such immunosti...

journal_title：Cancer immunology research

authors： Galluzzi L,Zitvogel L,Kroemer G

更新日期：2016-11-01 00:00:00

abstract：:The TNF receptor family member OX40 promotes activation and proliferation of T cells, which fuels efforts to modulate this immune checkpoint to reinforce antitumor immunity. Besides T cells, NK cells are a second cytotoxic lymphocyte subset that contributes to antitumor immunity, particularly in leukemia. Accordingly,...

journal_title：Cancer immunology research

authors： Nuebling T,Schumacher CE,Hofmann M,Hagelstein I,Schmiedel BJ,Maurer S,Federmann B,Rothfelder K,Roerden M,Dörfel D,Schneider P,Jung G,Salih HR

更新日期：2018-02-01 00:00:00

abstract：:Caspase recuitment domain-containing protein 9 (CARD9) functions in different inflammation pathways to elicit responses to microbial signals and is known to affect intestinal inflammation. Examining the APC(min) mouse model of intestinal tumorigenesis and using stringently controlled, sex- and age-matched pairs of CAR...

journal_title：Cancer immunology research

authors： Leo VI,Tan SH,Bergmann H,Cheah PY,Chew MH,Lim KH,Ruland J,Reilly PT

更新日期：2015-07-01 00:00:00

abstract：:Regulatory T cells (Treg) have long been considered one-sided suppressors of antitumor immune responses and hence associated with poor patient outcome in cancer. However, evidence is mounting of a paradoxical positive prognostic effect of Tregs on certain malignancies, including urinary bladder cancer (UBC). This disc...

journal_title：Cancer immunology research

authors： Winerdal ME,Krantz D,Hartana CA,Zirakzadeh AA,Linton L,Bergman EA,Rosenblatt R,Vasko J,Alamdari F,Hansson J,Holmström B,Johansson M,Winerdal M,Marits P,Sherif A,Winqvist O

更新日期：2018-05-01 00:00:00

abstract：:Monoclonal antibodies (mAb) can modulate cancer cell signal transduction and recruit antitumor immune effector mechanisms-including antibody-dependent cellular cytotoxicity (ADCC). Although several clinically effective antibodies can promote ADCC, therapeutic resistance is common. We hypothesized that oncogenic signal...

journal_title：Cancer immunology research

authors： Murray JC,Aldeghaither D,Wang S,Nasto RE,Jablonski SA,Tang Y,Weiner LM

更新日期：2014-12-01 00:00:00

abstract：:Hypoxia-driven, A2A adenosine receptor (A2AR)-mediated (hypoxia-A2-adenosinergic), T-cell-autonomous immunosuppression was first recognized as critical and nonredundant in protecting normal tissues from inflammatory damage and autoimmunity. However, this immunosuppressive mechanism can be highjacked by bacteria and tu...

journal_title：Cancer immunology research

authors： Sitkovsky MV,Hatfield S,Abbott R,Belikoff B,Lukashev D,Ohta A

更新日期：2014-07-01 00:00:00

abstract：:Natural killer (NK) cells contribute to clinical responses in patients treated with rituximab, but the rules determining NK-cell responsiveness to mAb therapies are poorly defined. A deeper understanding of the mechanisms responsible for antibody-dependent cellular cytotoxicity (ADCC) could yield useful biomarkers for...

journal_title：Cancer immunology research

authors： Du J,Lopez-Verges S,Pitcher BN,Johnson J,Jung SH,Zhou L,Hsu K,Czuczman MS,Cheson B,Kaplan L,Lanier LL,Venstrom JM

更新日期：2014-09-01 00:00:00

abstract：:The "cancer immunogenomics" paradigm has facilitated the search for tumor-specific antigens over the last 4 years by applying comprehensive cancer genomics to tumor antigen discovery. We applied this methodology to identify tumor-specific "neoantigens" in the C57BL/6-derived GL261 and VM/Dk-derived SMA-560 tumor model...

journal_title：Cancer immunology research

authors： Johanns TM,Ward JP,Miller CA,Wilson C,Kobayashi DK,Bender D,Fu Y,Alexandrov A,Mardis ER,Artyomov MN,Schreiber RD,Dunn GP

更新日期：2016-12-01 00:00:00

abstract：:Several host factors may affect the spread of cancer to distant organs; however, the intrinsic role of dendritic cells (DC) in controlling metastasis is poorly described. Here, we show in several tumor models that although the growth of primary tumors in Batf3-deficient mice, which lack cross-presenting DCs, was not d...

journal_title：Cancer immunology research

authors： Mittal D,Vijayan D,Putz EM,Aguilera AR,Markey KA,Straube J,Kazakoff S,Nutt SL,Takeda K,Hill GR,Waddell N,Smyth MJ

更新日期：2017-12-01 00:00:00

abstract：:Although immune checkpoint blockade (ICB) improves clinical outcome in several types of malignancies, pancreatic ductal adenocarcinoma (PDA) remains refractory to this therapy. Preclinical studies have demonstrated that the relative abundance of suppressive myeloid cells versus cytotoxic T cells determines the efficac...

journal_title：Cancer immunology research

authors： Li J,Yuan S,Norgard RJ,Yan F,Yamazoe T,Blanco A,Stanger BZ

更新日期：2020-03-01 00:00:00

abstract：:The presence and activity of CD8+ T cells within the tumor microenvironment are essential for the control of tumor growth. Utilizing B16-F10 melanoma tumors that express altered peptide ligands of chicken ovalbumin, OVA257-264, we measured high- and low-affinity OVA-specific responses following adoptive transfer of OT...

journal_title：Cancer immunology research

authors： Snook JP,Soedel AJ,Ekiz HA,O'Connell RM,Williams MA

更新日期：2020-04-01 00:00:00

abstract：:Tumors use various mechanisms to avoid immune destruction. Cyclooxygenase-2 (COX-2) expression may be a driver of immune suppression in melanoma, but the mechanisms involved remain elusive. Here, we show that COX-2 expression drives constitutive expression of indoleamine 2,3-dioxygenase 1 (IDO1) in human tumor cells. ...

journal_title：Cancer immunology research

authors： Hennequart M,Pilotte L,Cane S,Hoffmann D,Stroobant V,Plaen E,Van den Eynde BJ

更新日期：2017-08-01 00:00:00

abstract：:Cancer-testis (CT) antigens are attractive tumor antigens for cancer immunotherapy. They comprise a group of proteins normally expressed in germ cells and aberrantly activated in a variety of human cancers. The protein expression of eight cancer-testis antigens [MAGEA, NY-ESO-1, GAGE, MAGEC1 (CT7), MAGEC2 (CT10), CT45...

journal_title：Cancer immunology research

authors： Chen YT,Panarelli NC,Piotti KC,Yantiss RK

更新日期：2014-05-01 00:00:00

abstract：:Innate lymphoid cells (ILC) are responsible for mucosal tissue homeostasis and are involved in the progression and suppression of several types of cancer. However, the effects of ILCs on colorectal cancer are poorly understood. We characterized human ILCs in normal colon and colorectal cancer tissue, investigating the...

journal_title：Cancer immunology research

authors： Ikeda A,Ogino T,Kayama H,Okuzaki D,Nishimura J,Fujino S,Miyoshi N,Takahashi H,Uemura M,Matsuda C,Yamamoto H,Takeda K,Mizushima T,Mori M,Doki Y

更新日期：2020-06-01 00:00:00

abstract：:Multiple myeloma is characterized by the clonal expansion of malignant plasma cells in the bone marrow. But the phenotypic diversity and the contribution of less predominant B-lineage clones to the biology of this disease have been controversial. Here, we asked whether cells bearing the dominant multiple myeloma immun...

journal_title：Cancer immunology research

authors： Hansmann L,Han A,Penter L,Liedtke M,Davis MM

更新日期：2017-09-01 00:00:00

abstract：:Immune checkpoint inhibitors are promising treatments for patients with a variety of malignancies. Toward understanding the determinants of response to immune checkpoint inhibitors, it was previously demonstrated that the presence of somatic mutations is associated with benefit from checkpoint inhibition. A hypothesis...

journal_title：Cancer immunology research

authors： Nathanson T,Ahuja A,Rubinsteyn A,Aksoy BA,Hellmann MD,Miao D,Van Allen E,Merghoub T,Wolchok JD,Snyder A,Hammerbacher J

更新日期：2017-01-01 00:00:00

abstract：:Ligation of GITR (glucocorticoid-induced tumor necrosis factor (TNF) receptor-related gene, or TNFRSF18) by agonist antibody has recently entered into early phase clinical trials for the treatment of advanced malignancies. Although the ability of GITR modulation to induce tumor regression is well-documented in preclin...

journal_title：Cancer immunology research

authors： Schaer DA,Budhu S,Liu C,Bryson C,Malandro N,Cohen A,Zhong H,Yang X,Houghton AN,Merghoub T,Wolchok JD

更新日期：2013-11-01 00:00:00

abstract：:Type I interferon (IFN-I) is a class of antiviral immunomodulatory cytokines involved in many stages of tumor initiation and progression. IFN-I acts directly on tumor cells to inhibit cell growth and indirectly by activating immune cells to mount antitumor responses. To understand the role of endogenous IFN-I in spont...

journal_title：Cancer immunology research

authors： Castiello L,Sestili P,Schiavoni G,Dattilo R,Monque DM,Ciaffoni F,Iezzi M,Lamolinara A,Sistigu A,Moschella F,Pacca AM,Macchia D,Ferrantini M,Zeuner A,Biffoni M,Proietti E,Belardelli F,Aricò E

更新日期：2018-06-01 00:00:00

abstract：:The relationship between the adaptive CD4+ T cell response and human cancer is unclear. The oncofetal antigen 5T4 is expressed on many human carcinomas, including colorectal cancer (CRC) cells, but has limited expression on normal tissues. We previously identified anti-5T4 CD4+ T cells in a proportion of CRC patients,...

journal_title：Cancer immunology research

authors： Scurr M,Bloom A,Pembroke T,Srinivasan R,Brown C,Smart K,Bridgeman H,Davies M,Hargest R,Phillips S,Christian A,Hockey T,Gallimore A,Godkin A

更新日期：2013-12-01 00:00:00

abstract：:SLAMF6, a member of the SLAM (signaling lymphocyte activation molecules) family, is a homotypic-binding immune receptor expressed on NK, T, and B lymphocytes. Phosphorylation variance between T-cell subclones prompted us to explore its role in anti melanoma immunity. Using a 203-amino acid sequence of the human SLAMF6...

journal_title：Cancer immunology research

authors： Eisenberg G,Engelstein R,Geiger-Maor A,Hajaj E,Merims S,Frankenburg S,Uzana R,Rutenberg A,Machlenkin A,Frei G,Peretz T,Lotem M

更新日期：2018-02-01 00:00:00

abstract：:Solid tumors are refractory to cellular immunotherapies in part because they contain suppressive immune effectors such as myeloid-derived suppressor cells (MDSCs) that inhibit cytotoxic lymphocytes. Strategies to reverse the suppressive tumor microenvironment (TME) should also attract and activate immune effectors wit...

journal_title：Cancer immunology research

authors： Parihar R,Rivas C,Huynh M,Omer B,Lapteva N,Metelitsa LS,Gottschalk SM,Rooney CM

更新日期：2019-03-01 00:00:00

abstract：:Immunotherapies targeting T lymphocytes are revolutionizing cancer therapy but only benefit a subset of patients, especially in colorectal cancer. Thus, additional insight into the tumor microenvironment (TME) is required. Eosinophils are bone marrow-derived cells that have been largely studied in the context of aller...

journal_title：Cancer immunology research

authors： Reichman H,Itan M,Rozenberg P,Yarmolovski T,Brazowski E,Varol C,Gluck N,Shapira S,Arber N,Qimron U,Karo-Atar D,Lee JJ,Munitz A

更新日期：2019-03-01 00:00:00

abstract：:One limiting factor of CAR T-cell therapy for treatment of solid cancers is the suppressive tumor microenvironment (TME), which inactivates the function of tumor-infiltrating lymphocytes (TIL) through the production of immunosuppressive molecules, such as adenosine. Adenosine inhibits the function of CD4+ and CD8+ T c...

journal_title：Cancer immunology research

authors： Siriwon N,Kim YJ,Siegler E,Chen X,Rohrs JA,Liu Y,Wang P

更新日期：2018-07-01 00:00:00